Abstract

Background: Six cycles of temozolomide is the standard adjuvant-phase therapy for patients with newly-diagnosed glioblastoma after surgery and concomitant chemo-radiotherapy . Nevertheless, if well-tolerated, adjuvant-phase temozolomide is often continued beyond six cycles. While it remains inconclusive whether prolonged adjuvant-phase temozolomide improves survival, the haematological toxicities associated with lengthening the adjuvant therapy remained understudied.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call